"Current therapy for CML is with tyrosine kinase inhibitors (TKIs) which effectively hold back the disease, but do not cure it.
If the therapy is stopped, the leukaemia relapses in the majority of patients, requiring CML patients to remain on treatment for their lifetime."
Experts say these drugs, as well as being costly to administer, can cause a number of side effects including diabetes and vascular problems.
It is the dual issues of cost and toxicity in current CML treatment that has driven this particular piece of research.
The study, Dual targeting of p53 and c-Myc selectively eliminates leukaemic stem cells, is published in Nature.""
See also Cure possible for CML?